Veraxa Biotech AG - Post de-SPAC (VRXA) Cash from Financing Activities (2025)
Veraxa Biotech AG - Post de-SPAC's (VRXA) quarterly Cash from Financing Activities came in at $125117.0 in Q4 2025.
Powered by 
Analysis
Veraxa Biotech AG - Post de-SPAC (VRXA) Cash from Financing Activities (2025) Analysis & Trends
Veraxa Biotech AG - Post de-SPAC (VRXA) has reported Cash from Financing Activities for 1 consecutive years, with $125117.0 the latest figure, recorded in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | -1.48 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 2.34 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | -426.70 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | -1.22 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 14.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 1.30 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -181.51 Mn |
| 10 | Veraxa Biotech AG - Post de-SPAC | 23.88 Mn | 20.47 Mn | - | 125,116.98 |